https://www.selleckchem.com/pr....oducts/PHA-739358(Da
09% and 4.04%, respectively (both p 0.05), at 72weeks. The incidence of vertebral and non-vertebral fractures was similar in both groups. Bone formation markers increased in the teriparatide group and decreased in the alendronate group. The non-inferiority of once-weekly teriparatide versus once-weekly alendronate in BMD change at 72weeks was not shown, but the increase in bone formation markers over time and the increase of BMD in GIOP patients treated with once-weekly teriparatide were confirmed. The non-inferiorit
Aimer
Commentaire
Partagez
